First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation

Blood

Volumn 106, Issue 13, 2005, Pages 4377-4380

  Fraser, Christopher J ^a   Hirsch, Betsy A ^b   Dayton, Vanessa ^b   Creer, Michael H ^b   Neglia, Joseph P ^b   Wagner, John E ^b   Baker, K Scott ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; STEROID; THYMOCYTE ANTIBODY; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; DONOR; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS X; HUMAN; INFANT; LABORATORY TEST; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; UMBILICAL CORD BLOOD;

EID: 28844442334     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2551     Document Type: Article

References (25)

1. Cooley LD, Sears DA, Udden MM, et al. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol. 2000;63:46-53.
2. Bielorai B, Deeg HJ, Weintraub M, et al. B cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation. Bone Marrow Transplant. 2003;31:931-934.
3. Au WY, Chan EC, Siu LLP, et al. Leukemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma. Br J Haematol. 2002;119:777-780.
4. Gopcsa L, Barta A, Banyai A, et al. Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 2002;29:449-452.
5. Saito Y, Uzuka Y, Sakai N, et al. A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Bone Marrow Transplant. 2000;25:1209-1211.
6. Lawler M, Locasciulli A, Longoni D, et al. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant. 2002;29:453-456.
7. Brunstein CG, Hirsch BA, Hammerschmidt D, et al. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2002;29:999-1003.
8. Steinbrook R. The cord blood bank controversies. N Engl J Med. 2004;351:2255-2257.
9. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611-1618.
10. Mitelman F. ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger Publications; 1995.
11. Scharf SJ, Smith AG, Hansen JA, et al. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood. 1995;85:1954-1963.
12. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/ Mitelman. Accessed August 8, 2005.
13. Bhatia S, Bhatia R. Secondary malignancies after hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. Malden, MA: Blackwell Publishing; 2004:962-977.
14. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352-1358.
15. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998;91:1833-1844.
16. Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas and other solid tumors: the LCH-malignancy study group of the Histiocyte Society. Hematol Oncol Clin North Am. 1998;12:369-378.
17. Surico G, Muggeo P, Rigillo N, et al. Concurrent Langerhan's cell histiocytosis and myelodysplasia in children. Med Pediatr Oncol. 2000;35:421-425.
18. Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A. 1997;94:13950-13954.
19. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;94:1057-1062.
20. Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood. 2002;99:3801-3805.
21. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A. 2002;99:8242-8247.
22. Meyer EA, Hanna K, Gebbie K, eds. Cord blood: establishing a national hematopoietic stem cell bank program. Washington, DC: The National Academies Press; 2005.
23. Sugarman J, Kurtzberg J, Box TL, et al. Optimization of informed consent for umbilical cord blood banking. Am J Obstet Gynecol. 2002;187:1642-1646.
24. Sugarman J, Kaalund V, Kodish E, et al. Ethical issues in umbilical cord blood banking. JAMA. 1997;278:938-943.
25. Lecchi, L, Rebulla P, Ratti I, et al. Outcomes of a program to evaluate mother and baby 6 months after umbilical cord blood donation. Transfusion. 2001;41:606-610.